Resultado de búsqueda
9 de may. de 2024 · The past 45 years of p53 research represent a remarkable journey. As discussed previously, countless discoveries result in a much better understanding of the complexity of p53 functions under different physiological settings.
16 de may. de 2024 · 16 May 2024. Vol 384, Issue 6697. pp. 785 - 792. DOI: 10.1126/science.adh7950. Contents. Editor’s summary. Abstract. DNA damage inhibits translation. DNA damage causes ribosome stalling. Translation inhibition and ribosome stalling require SLFN11. SLFN11 mediates p53-independent apoptosis.
10 de may. de 2024 · Abstract. Clear-cell renal cell carcinoma (ccRCC), the major subtype of RCC, is frequently diagnosed at late/metastatic stage with 13% 5-year disease-free survival. Functional inactivation of the wild-type p53 protein is implicated in ccRCC therapy resistance, but the detailed mechanisms of p53 malfunction are still poorly characterized.
13 de may. de 2024 · MDM2 influences tumor development and progression in breast cancer through multiple pathways. Firstly, P21 is a downstream cell cycle protein kinase inhibitor of P53, and in breast cancer, it can block cell cycle progression, exerting an anti-cancer effect.
Hace 6 días · Such genetic studies attest P53 activation as quality control meant to eliminate genomically unfit cells with minimal involvement in the actual function of microcephaly associated genes. In this review, we summarize the known role of P53 activation in a variety of microcephaly models and introduce a novel mechanism wherein entotic cell cannibalism in neural progenitors is triggered by P53 ...
20 de may. de 2024 · TP53 mutations are found in 5%-10% of de novo myelodysplastic syndrome (MDS) and AML cases. By contrast, in therapy related MDS and AML, mutations in TP53 are found in up to 30%-40% of patients. The majority of inactivating mutations observed in MDS and AML are missense mutations localized in a few prevalent hotspots. TP53 missense mutations together with truncating mutations or chromosomal ...
2 de may. de 2024 · Our results uncover a novel role of GD3S in inhibiting p53-mediated apoptosis and promoting mutant p53–induced tumor initiation. To investigate the p53-mediated regulation of GD3S expression, we used the TCGA and METABRIC datasets and examined GD3S mRNA expression in breast tumors with different p53 mutation status.
